Analysis of the functional repertoire of a mutant form of survivin, K129E, which has been linked to lung cancer

Cancer Cell International

Sally P Wheatley²  Jamie RM Webster¹  Aysha M Aljaberi² 

[1] Present address: Protein Expression Facility, School of Cancer Sciences, University of Birmingham, Vincent Drive, Birmingham B15 2TT, UK;School of Life Sciences, University of Nottingham, Queen’s Medical Centre, Nottingham NG7 2UH, UK

关键词: Polymorphism;    Cancer;    Apoptosis;    Cytokinesis;    Mitosis;    Borealin;    Survivin;   

Others  :  1121671
DOI  :  10.1186/s12935-014-0078-8

 received in 2014-06-23, accepted in 2014-07-29,  发布年份 2014

【 摘 要 】

Background

Survivin is a protein that is normally present only in G2 and M-phases in somatic cells, however, in cancer cells, it is expressed throughout the cell cycle. A prosurvival factor, survivin is both an inhibitor of apoptosis and an essential mitotic protein, thus it has attracted much attention as a target for new oncotherapies. Despite its prevalence in cancer, reports of survivin mutations have mostly been restricted to loci within its promoter, which increase the abundance of the protein. To date the only published mutation within the coding sequence is an adenine > guanine substitution in exon 4. This polymorphism, which was found in a cohort of Korean lung cancer patients, causes a lysine > glutamic acid mutation (K129E) in the protein. However, whether it plays a causative role in cancer has not been addressed.

Methods

Using site directed mutagenesis we recapitulate K129E expression in cultured human cells and assess its anti-apoptotic and mitotic activities.

Results

K129E retains its anti-apoptotic activity, but causes errors in mitosis and cytokinesis, which may be linked to its reduced affinity for borealin.

Conclusion

K129E expression can induce genomic instability by introducing mitotic aberrations, thus it may play a causative role in cancer.

【 授权许可】

   
2014 Aljaberi et al.; licensee Springer

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Velculescu VE, Madden SL, Zhang L, Lash AE, Yu J, Rago C, Lal A, Wang CJ, Beaudry GA, Ciriello KM, Cook BP, Dufault MR, Ferguson AT, Gao Y, He T-C, Hermeking H, Hiraldo SK, Hwang PM, Lopez MA, Luderer HF, Mathews B, Petroziello JM, Polyak K, Zawel L, Zhang W, Zhang X, Zhou W, Haluska FG, Jen J, Sukumar S, et al.: Analysis of human transcriptomes. Nat Genet 1999, 23(3):387-388.
• [2]Zaffaroni N, Pennati M, Daidone MG: Survivin as a target for new anticancer interventions. J Cell Mol Med 2005, 9(2):360-372.
• [3]Altieri DC: Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008, 8:61-70.
• [4]Boidot R, Vegran F, Lizard-Nacol S: Transcriptional regulation of the survivin gene. Mol Biol Rep 2014, 41:233-240.
• [5]Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M: Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002, 277(5):3247-3257.
• [6]Jang JS, HKim KM, Kang KH, Choi JE, Lee WK, Kim CH, Kang YM, Kam S, Kim I-S, Jun JE, Jung TH, Park JY: Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer 2008, 60:31-39.
• [7]Xu Y, Fang F, Ludewig G, Jones G, Jones D: A mutation found in the promoter region of the human survivin gene is correlated with overexpression of survivin in cancer cells. DNA Cell Biol 2004, 9:527-537.
• [8]Antonacopoulou AG, Floratou K, Bravou V, Kottorou A, Dimitrakopoulos F-I, Marousi S, Stavropoulos M, Koutras AK, Scopa CD, Kalofonos HP: The survivin −31 snp in human colorectal cancer correlates with survivin splice variant expression and improved overall survival.Cell Oncol 2011. epub 3rd.
• [9]Verdecia MA, Huang H, Dutil E, Kaiser DA, Hunter T, Noel JP: Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement. Nat Struct Biol 2000, 7(7):602-608.
• [10]Colnaghi R, Connell CM, Barrett RMA, Wheatley SP: Separating the anti-apoptotic and mitotic roles of survivin. J Biol Chem 2006, 281(44):33450-33456.
• [11]Connell CM, Colnaghi R, Wheatley SP: Nuclear survivin has reduced stability and is not cytoprotective. J Biol Chem 2008, 238:3289-3296.
• [12]Stauber RH, Mann W, Knauer SK: Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. Cancer Res 2007, 67(13):5999-6002.
• [13]Carvalho A, Carmena M, Sambade C, Earnshaw WC, Wheatley SP: Survivin is required for stable checkpoint activation in response to loss of spindle tension in HeLa cells. J Cell Sci 2003, 116(14):2987-2998.
• [14]Lens SM, Medema RH: The survivin/Aurora B complex: its role in coordinating tension and attachment. Cell Cycle 2003, 2:507-510.
• [15]Ruchaud S, Carmena M, Earnshaw WC: Chromosomal passengers: conducting cell division. Nat Rev Mol Cell Biol 2007, 8:798-812.
• [16]Vader G, Medema R, Lens SMA: The chromosomal passenger complex: guiding Aurora-B through mitosis. J Cell Biol 2006, 173(6):833-837.
• [17]Jeyaprakash AA, Klein UR, Lindner D, Ebert J, Nigg EA, Conti E: Structure of a survivin-borealin-INCENP core complex reveals how chromosomal passengers travel together. Cell 2007, 131:271-285.
• [18]Lens SMA, Rodriguez JA, Vader G, Span SW, Giaccone G, Medema RH: Uncoupling the central spindle-associated function of the chromosomal passenger complex from its role at centromeres. Mol Biol Cell 2006, 17:1897-1909.
• [19]Wang F, Dai J, Daum JR, Niedzialkowska E, Banerjee B, Stukenberg PT, Gorbsky GJ, Higgins JMG: Histone H3 Thr-3 phosphorylation by haspin positions aurora B at centromeres in mitosis. Science 2010, 330(6001):231-235.
• [20]Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE: A visualization system for exploratory research and analysis. J Comput Chem 2004, 25(13):1605-1612.
• [21]Wang HJ, Holloway MP, Ma L, Cooper ZA, Riolo M, Samkari A, Elenitoba-Johnson KSJ, Chin YE, Altura RA: Acetylation directs survivin nuclear localization to repress STAT3 oncogenic activity. J Biol Chem 2010, 285(46):36129-36137.
• [22]Wheatley SP, Barrett RMA, Andrews PD, Medema RH, Morley SJ, Swedlow JR, Lens SMA: Phosphorylation of aurora-B negatively regulates survivin function during mitosis. Cell Cycle 2007, 6(10):1220-1230.